D.E. Shaw & Co
AQST icon

D.E. Shaw & Co’s Aquestive Therapeutics AQST Stock Holding History

D.E. Shaw & Co’s Portfolio AQST Stock Details AQST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$157K Buy
37,640
+19,491
+107% +$82K ﹤0.01% 4585
2026
Q1 		$75.3K Sell
18,149
-923,048
-98% -$3.75M ﹤0.01% 4312
2025
Q4 		$6.08M Buy
941,197
+915,697
+3,591% +$5.71M ﹤0.01% 2146
2025
Q3 		$143K Sell
25,500
-39,176
-61% -$169K ﹤0.01% 4322
2025
Q2 		$214K Sell
64,676
-114,359
-64% -$328K ﹤0.01% 4034
2025
Q1 		$519K Buy
179,035
+52,571
+42% +$159K ﹤0.01% 3487
2024
Q4 		$450K Buy
126,464
+95,418
+307% +$440K ﹤0.01% 3680
2024
Q3 		$155K Buy
31,046
+20,858
+205% +$81.2K ﹤0.01% 4206
2024
Q2 		$26.5K Sell
10,188
-85,025
-89% -$284K ﹤0.01% 4256
2024
Q1 		$406K Buy
+95,213
New +$317K ﹤0.01% 3590
2022
Q3 		– Sell
-164,607
Closed -$106K – 5167
2022
Q2 		$106K Buy
164,607
+55,769
+51% +$74.2K ﹤0.01% 4714
2022
Q1 		$284K Buy
108,838
+21,052
+24% +$61.5K ﹤0.01% 4679
2021
Q4 		$341K Buy
+87,786
New +$441K ﹤0.01% 4618
2020
Q3 		– Sell
-283,418
Closed -$1.38M – 3807
2020
Q2 		$1.38M Buy
283,418
+69,196
+32% +$319K ﹤0.01% 2697
2020
Q1 		$469K Sell
214,222
-49,195
-19% -$187K ﹤0.01% 3241
2019
Q4 		$1.53M Buy
+263,417
New +$1.37M ﹤0.01% 2684

Other funds holding AQST

BCM
Bratton Capital Management Fort Worth, Texas $40.8M AUM 25.68% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return

D.E. Shaw & Co's AQST Position: Q2 2026 in Review

D.E. Shaw & Co increased its Aquestive Therapeutics (AQST) stake by 107% in Q2 2026, buying an estimated $82K and bringing the position to 37,640 shares worth $157K. The position accounts for ﹤0.01% of the portfolio, ranked #4585.

D.E. Shaw & Co first reported a position in AQST in Q4 2019 and has held it in 16 quarters since. The position peaked at $6.08M in Q4 2025. 185 funds tracked by Wall St. Rank hold AQST as of Q2 2026.

  • D.E. Shaw & Co held 37,640 shares of Aquestive Therapeutics worth $157K as of Q2 2026.
  • D.E. Shaw & Co bought 19,491 Aquestive Therapeutics shares in Q2 2026, an estimated $82K.
  • Aquestive Therapeutics made up ﹤0.01% of D.E. Shaw & Co's portfolio in Q2 2026, its #4585 holding.
  • D.E. Shaw & Co first reported a position in Aquestive Therapeutics in Q4 2019 and has held it in 16 quarters since.
  • D.E. Shaw & Co's Aquestive Therapeutics position peaked at $6.08M in Q4 2025.
  • 185 funds tracked by Wall St. Rank held Aquestive Therapeutics as of Q2 2026.

Based on D.E. Shaw & Co's 13F filing for Q2 2026, filed 14 Aug 2026.